江西医药2012年5月第47卷第5期JiangxiMedicalJournal，May2012，Vol47，No5[20]。这些研究提示阿利吉仑可能比传统的ACE抑制剂和ARB更能抑制RAS活性，尤其是在组织水平和细胞水平。因此，阿利吉仑这些与传统RAS系统阻断剂的不同点可能给临床治疗带来新的机会。参考文献[1]DongYF,LiuL,KataokaK,etal.Aliskirenpreventscardiovascu鄄larcomplicationsandpancreaticinjuryinamousemodelofobesi鄄tyandtype2diabetes.Diabetologia,2010,53(1):180.[2]DongYF,KataokaK,ToyamaK,etal.AttenuationofbraindamageandcognitiveimpairmentbydirectRenininhibitioninmicewithchroniccerebralhypoperfusion.Hypertension,2011,58(4):635.[3]YamamotoE,KataokaK,DongYF,etal.Aliskirenenhancestheprotectiveeffectsofvalsartanagainstcardiovascularandrenalin鄄juryinendothelialnitricoxidesynthase-deficientmice.Hyperten鄄sion,2009,54(3):633.[4]DongYF,LiuL,LaiZF,etal.Aliskirenenhancesprotectiveeffectsofvalsartanagainsttype2diabeticnephropathyinmice.JHyper鄄tens,2010,28(7):1554.[5]AtlasSA.Therenin-angiotensinaldosteronesystem:pathophysio鄄logicalroleandpharmacologicinhibition.JManagCarePharm,2007,13(8SupplB):9.[6]BrownMJ.Aliskiren.Circulation,2008,118(7):773.[7]WoodJM,MaibaumJ,RahuelJ,etal.Structure-baseddesignofaliskiren,anovelorallyeffectiverenininhibitor.BiochemBiophysResCommun,2003,308(4):698.[8]AziziM,MenardJ,BisseryA,etal.PharmacologicdemonstrationofthesynergisticeffectsofacombinationoftherenininhibitoraliskirenandtheAT1receptorantagonistvalsartanonthean鄄giotensinII-reninfeedbackinterruption.JAmSocNephrol,2004,15(12):3126.[9]VanKatsJP,DunckerDJ,HaitsmaDB,etal.Angiotensin-convert鄄ingenzymeinhibitionandangiotensinIItype1receptorblockadepreventcardiacremodelinginpigsaftermyocardialinfarction:roleoftissueangiotensinII.Circulation,2000,102(13):1556.[10]KimS,IwaoH.MolecularandcellularmechanismsofangiotensinII-mediatedcardiovascularandrenaldiseases.PharmacolRev,2000,52(1):11.[11]DanserAH,KoningMM,AdmiraalPJ,etal.Metabolismofan鄄giotensinIbydifferenttissuesintheintactanimal.AmJPhysiol,1992,263:H418.[12]AldermanMH.Plasmareninactivityandcoronaryheartdisease:aretheyrelated?CurrOpinNephrolHypertens,1995,4(2):201.[13]MuhlesteinJB,MayHT,BairTL,etal.Relationofelevatedplas鄄mareninactivityatbaselinetocardiaceventsinpatientswithan鄄giographicallyprovencoronaryarterydisease.AmJCardiol,106(6):764.[14]TaylorAAAD,AroraV.Reninsystemsuppressionwiththeoraldirectrenininhibitoraliskirenadministeredaloneorincombina鄄tion:apooledanalysisof1093patientswithhypertension.JAmCollCardiol,2007,49(SupplA):370A.[15]FeldtS,MaschkeU,DechendR,etal.Theputative(pro)reninre鄄ceptorblockerHRPfailstoprevent(pro)reninsignaling.JAmSocNephrol,2008,19(4):743.[16]HuangY,WongamornthamS,KastingJ,etal.Reninincreasesmesangialcelltransforminggrowthfactor-beta1andmatrixpro鄄teinsthroughreceptor-mediated,angiotensinII-independentmechanisms.KidneyInt,2006,69(1):105.[17]OparilS,YarowsSA,PatelS,etal.Efficacyandsafetyofcombineduseofaliskirenandvalsartaninpatientswithhypertension:arandomised,double-blindtrial.Lancet,2007,370(9583):221.[18]FisherND,HollenbergNK.Renininhibition:whatarethethera鄄peuticopportunities?JAmSocNephrol,2005,16(3):592.[19]KumarR,SinghVP,BakerKM.Theintracellularrenin-an鄄giotensinsystemintheheart.CurrHypertensRep,2009,11(2):104.[20]SinghVP,LeB,KhodeR,etal.IntracellularangiotensinIIpro鄄ductionindiabeticratsiscorrelatedwithcardiomyocyteapoptosis,oxidativestress,andcardiacfibrosis....
